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HD1 and HD22 are two of the most-studied aptamers binding to thrombin exosite
I and exosite, respectively. To complete of their pharmacological profiles, the effects
of HD1 and HD22 on thrombin-, ristocetin-, and collagen-induced human platelet
aggregation, on thrombin generation and fibrin formation in human plasma, as well as
on thrombus formation in human whole blood under flow conditions were assessed.
The dissociation constants for HD1 and HD22 complexes with thrombin in simulated
plasma ionic buffer were also evaluated. HD1 was more potent than HD22 in terms
of inhibiting thrombin-induced platelet aggregation in platelet-rich plasma (PRP; 0.05–
3 µM) and in washed platelets (WPs; 0.005–3 µM): approximately 8.31% (±6.99%
SD) and 89.53% (±11.38% SD) for HD1 (0.5 µM) and HD22 (0.5 µM), respectively.
Neither HD1 nor HD22 (3 µM) did influence platelets aggregation induced by collagen.
Both of them inhibited ristocetin-induced aggregation in PRP. Surprisingly, HD1 and
HD22 aptamers (3 µM) potentiated ristocetin-induced platelet aggregation in WP. HD1
reduced thrombin generation in a concentration-dependent manner [ETP at 3 µM:
1677.53 ± 55.77 (nM·min) vs. control 2271.71 ± 423.66 (nM·min)], inhibited fibrin
formation (lag time at 3 µM: 33.70 min ± 8.01 min vs. control 7.91 min ± 0.91 min) and
reduced thrombus formation under flow conditions [AUC30 at 3 µM: 758.30 ± 344.23
(kPa·min) vs. control 1553.84 ± 118.03 (kPa·min)]. HD22 (3 µM) also delayed thrombin
generation but increased the thrombin peak. HD22 (3 µM) shortened the lag time of
fibrin generation (5.40 min ± 0.26 min vs. control 7.58 min ± 1.14 min) but did not
modify thrombus formation (3, 15 µM). Kd values for the HD1 complex with thrombin
was higher (257.8 ± 15.0 nM) than the Kd for HD22 (97.6 ± 2.2 nM). In conclusion,
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HD1 but not HD22 represents a potent anti-thrombotic agent, confirming the major
role of exosite I in the action of thrombin. HD22 aptamer blocking exosite II displays
weaker anti-platelet and anti-coagulant activity, with surprising activating effects on
thrombin and fibrin generation most likely induced by HD22-induced allosteric changes
in thrombin dynamic structure.
Keywords: aptamers, platelets, thrombin generation, fibrin generation, thrombus formation
INTRODUCTION
Thrombin, a central enzyme of the coagulation cascade, plays
a crucial role in the formation, growth, and stabilization of
thrombi. Thrombin is a highly dynamic molecule involved
in the polymerization and stabilization of fibrin, proteolytic
and non-proteolytic activation of platelets as well as in the
amplification of thrombin generation by feedback activation of
upstream coagulation factors. These effects are mostly mediated
by thrombin exosite I, exosite II and the active site of the enzyme
(Di Cera, 2007; Petrera et al., 2009; Malovichko et al., 2013;
Pica et al., 2017).
Given the fact that increased thrombin activity is associated
with a variety of cardiovascular diseases (Danckwardt et al.,
2013), a number of direct anti-thrombin agents, targeted
selectively to thrombin sites, have been developed. For example,
bivalent recombinant bivalirudin binding to the active site and
exosite I, or univalent direct inhibitors including argatroban
and dabigatran binding only to the active site of thrombin
(Zavyalova et al., 2016). A number of thrombin binding aptamers
(TBAs) have also been recently developed. They represent a
promising class of direct anti-thrombin agents with high affinity
and specificity to thrombin exosite I or exosite II (Zavyalova
et al., 2016) and provide an interesting alternative for clinically
used therapeutics (Zhou and Rossi, 2017). The mechanisms of
aptamers activity is based on the direct blockage of functionally
important sites of thrombin structure resulting in altered
function and conformation changes (Petrera et al., 2009). Thus,
aptamers are also promising tools for studying the dynamics of
the thrombin enzyme molecule.
As regards the use of aptamer as therapeutics, degradation by
nucleases and unfavorable pharmacokinetics are limiting factors
for their wider therapeutic applications. Various approaches are
taken to reduce these limitations (Lakhin et al., 2013; Ni et al.,
2017). The use of chemical modification of oligonucleotides
including 2′-substitution of the sugar ring by -F, -NH2,
-OMe, -OH, -H, locked nucleic acid (LNA), unlocked nucleic
acid (UNA) or 2′-deoxy-2′-fluoro-D-arabinonucleic acid (2′-F
ANA) are only a few examples of solutions to generate
nuclease-resistant aptamers. The conjugation of polyethylene
glycol (PEG) to aptamers delay their renal filtration (Padilla and
Sousa, 1999; Sun et al., 2014; Ni et al., 2017; Maio et al., 2018).
The pharmacokinetic parameters of an aptamer could be also
controlled by an antidote being a complementary oligonucleotide
(Oney et al., 2010; Lakhin et al., 2013; Stoll et al., 2017).
Thrombin binding aptamers include uni- and bivalent
oligonucleotides (Müller et al., 2008; Yuminova et al., 2015; Hao
and Zhao, 2016; Zavyalova et al., 2016). There is a number of
thrombin-binding aptamers including DNA-type NU172, RA-36
binding to exosite I, RNA-type R9D-14T and Toggle-25t binding
to exosite I and exosite II, respectively, and DNA-type HD1-22,
RNV220, RNV220-T bivalent aptamers (Müller et al., 2008;
Yuminova et al., 2015; Hao and Zhao, 2016; Zavyalova et al.,
2016). However, HD1 and HD22 are the best known TBAs.
HD1, a 15-mer length oligonucleotide, has a quadruplex
structure and binds to thrombin exosite I (Pica et al., 2017), that
is positively charged, equipped with hydrophobic patches (Di
Cera, 2007), and binds fibrinogen, coagulation factors V, VIII, XI,
and XIII, thrombomodulin, heparin cofactor II and the PAR-1
platelet receptor (Verhamme et al., 2002; Bock et al., 2007; Müller
et al., 2008). HD1 aptamer inhibits thrombin-induced platelet
aggregation by limiting interactions of exosite I with the PAR-1
receptor (Boncler et al., 2001). Because the exosite I region is also
present in prothrombin, HD1 inhibits prothrombin activation
(Brummel-Ziedins et al., 2005; Kretz et al., 2006, 2010). Despite
a potentially interesting profile of HD1 action, it was excluded
from further clinical development, because of the lack of expected
efficacy and not optimal pharmacokinetic profile (Schwienhorst,
2006; Zavyalova et al., 2017).
HD22, a 29-mer length oligonucleotide, has a duplex-
quadruplex structure and interacts with thrombin exosite II
(Pica et al., 2017). Positively charged exosite II (Di Cera,
2007) interacts with coagulation factors V and VIII, heparin,
prothrombin factor F2 and the platelet GPIb-IX-V receptor
(Bock et al., 2007; Müller et al., 2008). HD22 was reported
to prolong thrombin-mediated clotting times and to affect
interaction of thrombin with fibrinogen (Müller et al., 2008).
Interestingly, both aptamers were reported to inhibit non-
catalytic fibrin polymerization (Mosesson, 2007) and to suppress
coagulation by blocking thrombin-mediated activation of factor
V (Segers et al., 2007).
Despite numerous studies, pharmacological effects of HD1
and HD22 are still not fully characterized and some results
seem difficult to explain (Tasset et al., 1997; Mosesson, 2007;
Müller et al., 2008). There is also a lack of studies in
which the mechanisms of their actions are comprehensively
compared. Therefore, in the present work, we have compared
the pharmacological effects of HD1 and HD22 using quite a
comprehensive approach to studying the effects of HD1 and
HD22 on platelets, thrombin generation, fibrin formation, and
thrombus formation.
We characterized effects of HD1 and HD22 on thrombin-,
collagen- and ristocetin-induced platelet aggregation in human
washed platelets (WPs) and in human platelet-rich plasma (PRP).
We also studied effects of HD1 and HD22 on thrombin and fibrin
generation in human platelet-poor plasma (PPP) and on thrombi
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formation in human whole blood under flow conditions using
Total Thrombus-formation Analysis System (T-TAS). Binding
characteristics of HD1 and HD22 to exosite I and exosite II
was performed in simulated body plasma ionic buffer (SBP) by
capillary electrophoresis (CE).
MATERIALS AND METHODS
Blood Collection
Venous blood was obtained from male volunteers at the
University Hospital Blood Bank Centre. Volunteer donors had
not taken any medicines for the preceding 2 weeks. Informed
consent was given by a volunteer prior to the blood withdrawal
and study conformed with the principles outlined in the World
Medical Association (WMA) Declaration of Helsinki as well as
Bioethical Commission of Jagiellonian University.
Aptamers Preparation
Fluorescein-labeled or non-labeled HD1 (5′-GGTTGGTGTG
GTTGG-3′) and HD22 (5′-AGTCCGTGGTAGGGCAGGTT
GGGGTGACT-3′) anti-thrombin aptamers (Bock et al., 1992;
Tasset et al., 1997) were synthetized by FUTURE Synthesis
(Lodz, Poland). Liophilizated anti-thrombin aptamers were
dissolved in nuclease-free water (Ambion, United States) and
stored at−20◦C.
Light Transmission Aggregometry (LTA)
Prior to measurements, blood samples from healthy volunteers
were collected in tubes containing 3.2% sodium citrate (volume
ratio: 9:1). Collected blood was centrifuged at 260× g for 15 min
at room temperature to obtain PRP and then at 2,600 × g for
20 min at room temperature to obtain PPP. PRP was pooled and
adjusted to 200,000 platelets/µl with ion-free phosphate-buffered
saline (PBS; Lonza, Switzerland) and immediately used for
platelet aggregation. PPP was used as blank in LTA carried out
in PRP or immediately frozen at −80◦C to be tested in thrombin
and fibrin generation assays at a later moment.
For the preparation of WPs, PRP was supplemented with
prostacyclin (100 ng/ml; Sigma-Aldrich, United States) and
centrifuged at 960 g for 10 min. The platelet pellet was
re-suspended in ion-free PBS, with addition of prostacyclin
(100 ng/ml) and then centrifuged at 810 × g for 10 min
at room temperature to obtain another platelet pellet. WP
were adjusted to 200,000 platelets/µl with ion-free PBS. After
a 30-min equilibration period, the platelet suspension was
supplemented with CaCl2 (Merck, Germany) and MgCl2·6H2O
(POCH, Poland) to final concentrations of 9.9× 10−4 mM (Ca2+
ions) and 2.1× 10−3 mM (Mg2+ ions), respectively, and used for
platelet aggregation.
Platelet aggregation was measured by turbidimetry at
37◦C under stirring using a Lumi-Aggregometer Model 700
(CHRONO-LOG, United States). For thrombin-induced platelets
aggregation tests in PRP, HD1 or HD22 aptamers at final
concentrations of 0.0, 0.05, 0.1, 0.3, 0.5, 1.5, and 3 µM were
preincubated for 2 min at 37◦C in the presence or in the absence
of Gly-Pro-Arg-Pro [GPRP, 1.2 mM (Boncler et al., 2001);
Sigma-Aldrich, United States], respectively. GPRP suppresses the
early stages of fibrin polymerization and was used in platelet
aggregation tests assayed in PRP to avoid generation of fibrin.
Fibrin fibers formed in plasma during the measurements in
Light Transmission Aggregometry (LTA) affect light transmission
through cuvettes. The formed fibrin nets intercalate platelets and
thrombin molecules which impedes HD1 and HD22 aptamers
interactions with these plasma components thus, studied effects
could be not only due to the direct effects of TBA on thrombin
activity. In the presence of 1.2 mM concentration of GPRP
there were no visible fibrin fibers inside the cuvettes. For
thrombin-induced platelets aggregation tests in WP, HD1 or
HD22 aptamers at final concentrations of 0.005, 0.01, 0.025, 0.05,
0.1, 0.3, 0.5, 1.5, and 3 µM were preincubated for 2 min at 37◦C.
Thrombin-induced platelets aggregation was also performed in
the presence of dabigatran in WP. In this case, dabigatran at 50
ng/ml, corresponding to the therapeutic range of dabigatran peak
plasma concentrations (Vinholt et al., 2017), was preincubated
for 2 min at 37◦C. For ristocetin- and collagen-induced platelets
aggregation tests in PRP and WP, HD1 or HD22 aptamers
at final concentration of 3 µM were preincubated for 2 min
at 37◦C. Then, platelets were stimulated with natural human
thrombin (0.5 U/ml; Abcam, GB), ristocetin (PRP: 0.75 mg/ml;
WP: 1 mg/ml; Biogenet, Poland) or collagen (2 µg/ml; Biogenet,
Poland). Platelet aggregation was monitored for 6 min and
results were presented as a percent of control aggregation for
thrombin- and collagen-induced aggregation tests and as platelets
aggregation expressed as a percentage for ristocetin-induced
platelet aggregation.
Calibrated Automated Thrombography
(CAT)
Immediately prior to measurements, frozen PPP plasma
samples were thawed at 37◦C. Thrombin generation in
control samples was activated by mixing 40 µl plasma
with 10 µl of fluorogenic substrate (Z-Gly-Gly-Arg-AMC,
16.6 mM; Thrombinoscope B.V., Netherlands) and 10 µl of
trigger solution containing phospholipids (PL, 4 µM), tissue
factor (TF, 1 pM) (Thrombinoscope B.V., Netherlands) and
CaCl2 (16.6 Mm). HD1 or HD22 aptamers were added to
reach the final concentrations of 0.5, 3 and 15 µM. In
the calibration wells, the 10 µl of reagents were replaced
with calibrator (complex of alpha 2 macroglobulin with
thrombin, α2M-T, 208 nM; Thrombinoscope B.V., Netherlands).
Immediately after the activation of thrombin generation, 60
µl of the mixture was pipetted into a flat-bottom 96-well
polystyrene plate. Fluorescence signals were measured using
a plate reader (λex. = 390 nm, λem. = 460 nm; Spark
Magellan R©, Tecan, Switzerland) and transformed into thrombin
concentration as described previously (Hemker et al., 2003;
Hemker and Kremers, 2013).
Furthermore, the effect of HD1 and HD22 aptamers
on thrombin activity toward fluorogenic substrate was
investigated. Fluorescence signal generation was triggered
by adding 10 µl BSA60 buffer (20 mM Hepes, 6% BSA,
0.02% NaN3; pH = 7.35; Thrombinoscope B.V., Netherlands)
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containing fluorogenic substrate (Z-Gly-Gly-Arg-AMC,
16.6 mM) to 50 µl of BSA60 buffer supplemented with human
thrombin (1 U/ml) and HD1 or HD22 aptamers (3 µM).
The reference systems were prepared as above but without
the aptamers. The fluorescence signal was recorded using the
plate reader (λex. = 390 nm, λem. = 460 nm; Spark Magellan R©,
Tecan, Switzerland).
Turbidimetry Measurements
Fibrin generation was triggered by addition of PPP to the wells
of the microtiter plate containing TF (0.5 pM), PL (4 µM)
and calcium ions (Ca2+, 10 mM) in the presence or absence
of HD1 or HD22 aptamers (3 µM). After mixing of PPP
with reagents, the turbidity of the solution was continuously
monitored by measuring absorbance using the plate reader
(λabs. = 405 nm; Spark Magellan R©, Tecan, Switzerland) at 37◦C.
The influence of HD1 and HD22 aptamers on fibrin generation
was evaluated in nine (n = 9) independent measurements. T1/2
values were calculated as time period that elapsed to obtain
the half of maximal plateau absorbance and was presented as
mean± SD (n = 9).
Total Thrombus-Formation Analysis
System (T-TAS)
Citrated whole blood was preincubated (2 min, room
temperature) with HD1 or HD22 anti-thrombin aptamers
(3 µM or 15 µM). Samples were mixed with a CaCl2 (12
Mm) solution containing corn trypsin inhibitor (CTI, 50
µg/ml; Zacros, Japan). After mixing, each blood sample was
immediately perfused over the microchip with thrombogenic
surfaces (collagen and tissue factor, atheroma AR chip; T-TAS;
Fujimori Kogyo Co., Ltd., Japan) at a flow rate of 4 µl/min. Flow
pressure changes were monitored by the pressure transducer
located upstream of the microcapillaries. The pressure pattern
for each sample was used to analyze thrombus formation
based on the following estimated parameters: time required to
reach 10 kPa from baseline pressure, reflecting onset time for
thrombus formation (T10; min); occlusion time (OT; min),
which is the time reflecting complete capillary occlusion and
area under a time vs. pressure curve (AUC30) obtained after
30 min (under 80 kPa) since the start of the assay, reflecting
total thrombogenicity.
Thrombus formation inside capillaries was recorded in real
time using a T-TAS CCD camera at 0, 3, 6, 9, and 12 min after
blood sample application and the start of the measurement. The
two-dimensional area covered by thrombi was analyzed by image
analysis software (Zia 4.0.0.1, Fujimori Kogyo Co., Ltd., Japan).
Capillary Electrophoresis (CE)
A P/ACE MDQ capillary electrophoresis system
(Beckman Coulter, Fullerton, CA, United States) with
a Laser-Induced Fluorescence (LIF) detector equipped
with an air-cooled argon laser (Beckman Instruments,
United States) with excitation at 488 nm and emission at
520 nm was used.
Simulated body plasma ionic buffer (SBP) was used as the
incubation buffer, prepared according to the European Standard
EN ISO 10993-15:2009 [NaCl (0.116 M), CaCl2 (0.002 M), KCl
(0.005 M), NaHCO3 (0.026 M) (Merck, Germany), MgSO4 (0.001
M), Na2HPO4·2H2O (0.001 M) and NaH2PO4 (0.00017 M)
(Sigma-Aldrich, United States)].
To evaluate interactions of aptamers with human thrombin,
the experiments were performed using a bare fused silica
capillary (BFS; 30.2 cm total length, 20 cm effective length,
50 µm i.d., 375 µm o.d., thermostated at 25◦C). Prior
to each run, the BFS capillary was rinsed with 0.1 M
NaOH (Sigma-Aldrich, United States), followed by H2O
and running buffer (275.8 kPa, 2 min for each). After
sample injection (hydrodynamic injection ∼20 nl; capillary
pressure pulse: 3.4 kPa, 10 s) separation was performed using
buffer (pH = 8.3) containing 20 mM TRIS and 9 mM
acetic acid (Sigma-Aldrich, United States). A voltage of +10
kV, which produced an electric field of approximately 333
V·cm−1, was used.
Fluorescein-labeled aptamers were used for evaluation of
interactions of aptamers with thrombin. Prior to analyses,
aptamers were heated to 95◦C (5 min) and then slowly cooled
to room temperature. Samples contained 400 nM thrombin and
100 nM aptamer prepared in SBP were incubated at 37◦C for
2 min before measurements. Control samples contained 100 nM
of each aptamer.
Calculations of Dissociation Constants
(Kd)
Kd calculations were based on the non-equilibrium capillary
electrophoresis of equilibrium mixtures (NECEEM) method
introduced by Krylov (2006). Briefly, a short plug of the
equilibrium mixture (consisting of ligand, its target and
complex which is created during incubation) is injected
into the inlet of the capillary. Separation is carried out
with the running buffer only. The complex continuously
dissociates during electrophoresis. If separation is efficient,
reassociation of target and ligand can be neglected. Consequently,
the characteristic electropherograms are obtained, which
contain peaks from free ligand, target and complex – and
two exponential ‘smears’ of ligand and target unleashed
during separation.
Statistical Calculations
Values are presented as mean ± SD. Normal distribution of
data was verified by Shapiro–Wilk test. Statistical significance
of differences between groups was estimated by an unpaired
t-test (ristocetin-induced platelet aggregation in PRP for
HD1 and in WP for HD1 and HD22), Mann–Whitney test
(ristocetin-induced platelet aggregation in PRP for HD22 and
T-TAS measurements), a non-parametric Kruskal–Wallis test
followed by post hoc multiple comparisons Dunn’s test (for CAT
measurements). A p-value < 0.05 was considered statistically
significant (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001).
Analyses were performed using GaphPad Prism 6.0 software.
The power of the test was verified by a post hoc T-test
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of differences between two independent means (α = 0.05).
Analysis of the test power was performed by G∗ Power
3.1.9.2 software.
RESULTS
Effects of HD1 and HD22 Aptamers on
Thrombin-, Collagen-, and
Ristocetin-Induced Platelet Aggregation
in Washed Platelets and in Platelet-Rich
Plasma
HD1 strongly inhibited thrombin-induced platelet aggregation
in a concentration-dependent manner (0.05–3.0 µM) in PRP
(Figure 1C). HD1 at 3 µM concentration caused total inhibition
of platelets aggregation in PRP, while HD22 (3 µM) inhibited
platelets aggregation to 35.22% of control (Figure 1D). At lower
concentrations, HD1 (0.5 µM) was about ten times more potent
than HD22 (0.5 µM) in terms of inhibiting thrombin-induced
platelet aggregation in PRP (8.31%± 6.99% vs. 89.53%± 11.38%,
respectively). The anti-thrombin effect of HD1 (0.005–3 µM) was
even stronger in WPs (Figure 1A), but the difference between
potency of HD1 and HD22 (Figure 1B) in WP was smaller
than in PRP.
HD1 and HD22 aptamers (3 µM) did not affect
collagen-induced platelet aggregation in PRP and
WP (Figures 2A–D).
HD1 and HD22 aptamers (3 µM) caused statistically
significant inhibition of ristocetin-induced platelet aggregation
(to 31.75% ± 26.88% and 18.00% ± 20.86% of control in PRP
(Figures 3C,D).
However, in WP, both HD1 and HD22 potentiated the
ristocetin-induced platelets aggregation (Figures 3A,B). The
percentage of platelets aggregation in WP was 49.38% (±12.65%
SD) or 50.25% (±6.54% SD) in the presence of HD1 or HD22
aptamer in contrast to control measurements of 22.63% (±8.68%
SD) or 33% (±10.30% SD), respectively.
FIGURE 1 | Effects of HD1 and HD22 aptamers on thrombin-induced platelet aggregation in WP (A,B) and in PRP (C,D). Data distribution is presented as median
with box plots and 25th and 75th percentile. Data mean is represented as a cross (n = 8).
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FIGURE 2 | Effects of HD1 and HD22 aptamers (3 µM) on collagen-induced (2 µg/ml) platelet aggregation in WP (A,B) and in PRP (C,D). Results are presented as
mean ± SD.
For comparison, we assessed effects if dabigatran at 50 ng/ml
(0.11 µM), which corresponds to the therapeutic range of
dabigatran peak plasma concentrations (Vinholt et al., 2017),
that resulted in total inhibition of platelets aggregation caused by
thrombin in WP (0%± 0% vs. 79.40%± 3.65% control, n = 5).
Effects of HD1 and HD22 Aptamers on
Thrombin Generation in Human
Platelet-Poor Plasma
HD1 aptamer inhibited thrombin generation in a
concentration-dependent manner, as evidenced by a
prolongation of the lag time and the time to peak, as well
as lowered values of peak and endogenous thrombin potential
(ETP) (Figure 4). HD1 at a concentration of 0.5 µM was not
effective while, at 3 µM HD1, it significantly prolonged the lag
time (from 4 to 10 min), the time to peak (from 7 to 12 min) and
decreased the ETP (from 2.270 to 1.670 nM·min) as compared
to control (Figure 4). HD1 aptamer at a concentration of 15
µM completely inhibited thrombin generation, as evidenced by
the readout of all four parameters (Figure 4). Effects of HD22
aptamer on thrombin generation were weaker as compared
with HD1. However, HD22 still prolonged the lag time and the
time to peak in a concentration-dependent manner, with about
a twofold increase of these parameters at a concentration of
15 µM (for the lag time from 4 to 8 min and the time to peak
from 7 to 13 min). Unlike HD1, HD22 was not reduced but it
rather tended to increase the height of the peak, particularly
at the concentration of 3 µM (from 364 nM to 511 nM), and
the ETP at the concentration of 3 µM and 15 µM (from 2.490
nM·min to 2.667 nM·min and to 2.927 nM·min, respectively) in
comparison to control.
HD22 enhanced thrombin catalytic activity toward the CAT
fluorogenic substrate. The fluorescence signal reached 4952 A.U.
after 60 min of measurement, in comparison with 3108 A.U. of
the control signal. In contrast, HD1 did not have an influence
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FIGURE 3 | Effects of HD1 and HD22 aptamers (3 µM) on ristocetin-induced platelet aggregation in WP (A,B; ristocetin at 1 mg/ml) and in PRP (C,D; ristocetin at
0.75 mg/ml). Results are presented as mean ± SD.
on fluorescence generation. The fluorescence signal reached 3403
A.U. after 60 min of measurement in comparison to 3316 A.U. of
the control signal.
Effect of HD1 and HD22 Aptamers on
Fibrin Formation in Platelet-Poor Plasma
HD1 aptamer at a concentration of 3 µM prolonged the lag time
by approximately 20 min in comparison to control (Figure 5A).
HD22 aptamer at the same concentration demonstrated the
opposite effect and shortened the lag time by approximately
1.5 min in comparison to control (Figure 5B). Calculated
t1/2 values were approximately 33.70 min ± 8.01 min and
5.40 min ± 0.26 min for HD1 and HD22, respectively, in
comparison to respective controls (7.91 min ± 0.91 min and
7.58 min ± 1.14 min, p < 0.0001). HD22 activity did not
influence the maximal absorbance (1.12 A.U.), which was close
to the control value (1.11 A.U.). A slight reduction of the
amount of generated fibrin was obtained for HD1, where the
maximal absorbance was 0.95 A.U. compared to 1.09 A.U.
for the control.
Effects of HD1 and HD22 on Thrombus
Formation in Human Whole Blood
HD1 inhibited thrombus formation in a microchip-based
chamber system (T-TAS) in a concentration-dependent manner
(3-15 µM), as evidenced by the delay of the start time of
thrombi formation (T10), the prolongation of the occlusion
time (OT) and reduction of total thrombogenicity (AUC30)
(Figure 6). HD1 at a concentration of 15 µM substantially
prolonged the occlusion time up to more than 30 min.
Additionally, fibrin formation was profoundly reduced by the
HD1 aptamer, as evidenced by observations of images inside
capillaries recorded by a T-TAS CCD camera (Figure 7).
HD1 aptamer at a concentration of 15 µM significantly
decreased the area covered by thrombi in microcapillaries
(3,6%) as compared to the corresponding control sample
(33.1%) measured at 12 min after blood sample application.
In contrast, HD22 had no impact on thrombus formation at
any studied concentrations (3–15 µM), as shown by unchanged
values of T10, OT and AUC30 (Figure 6). For a 15 µM
concentration of HD22 aptamer, the area inside the chip covered
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FIGURE 4 | Effects of HD1 and HD22 aptamers on thrombin generation assessed by calibrated automated thrombography (CAT) in human platelet poor plasma.
Results are presented as mean ± SD (nHD1 = 4, control of HD1 n = 12; nHD22 = 6, control of HD22 n = 15).
FIGURE 5 | Representative curves showing the effect of HD1 (3 µM) (A) and HD22 (3 µM) (B) on fibrin formation in human platelet poor plasma evaluated by
turbidimetry measurements. Results are presented as mean (solid line) ± SD (dotted line) obtained from four independent measurements.
by thrombi was 33.6%, which was similar to the control value
(31.2%) (Figure 7).
HD1 and HD22 Affinity to Human
Thrombin in Simulated Body Plasma
Ionic Buffer
As shown in Table 1, HD22 aptamer affinity to thrombin was
higher than that of HD1 as measured by capillary electrophoresis
in simulated body plasma ionic buffer (SBP).
DISCUSSION
In the present work, using a comprehensive approach, we
have compared the pharmacological effects of two thrombin
binding aptamers, HD1 and HD22. We characterized their
activity toward platelets and thrombin-dependent coagulation
processes in various assays including thrombin-, collagen-, and
ristocetin-induced platelet aggregation in human PRP and in
WPs, thrombin and fibrin generation in human PPP as well
as thrombus formation in human blood under flow conditions
encompassing platelets and coagulation cascade activity together
using a microchip-based system (T-TAS).
We demonstrated that HD1 is a potent anti-platelet,
anti-coagulant, and anti-thrombotic agent, underscoring the
major role of exosite I in the modulation of thrombin
action. In turn, although HD22 (an exosite II biding aptamer)
had a higher affinity to bind thrombin as evidenced by
lower Kd values, it displayed weaker anti-platelet activity in
WP and PRP as compared with that of HD1, displayed a
weaker anti-coagulant activity, with a surprising activating
effects on thrombin and fibrin generation most likely induced
by HD22-induced allosteric changes in thrombin dynamic
structure. HD22 did not display anti-thrombotic nor pro-
thrombotic effect on thrombus formation in human blood under
flow conditions.
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FIGURE 6 | Effect of HD1 and HD22 aptamers on thrombus formation in human blood in a microchip-based flow chamber system (Total Thrombus-formation
Analysis System, T-TAS). T10, thrombi formation starting time; OT, occlusion time; AUC30, area under time-pressure curve. Results are presented as mean ± SD (3
µM: nHD1 = 5, nHD22 = 3; 15 µM: nHD1 = 3, nHD22 = 5). Post hoc compute test power achieved p = 1.00 for all parameters (T10, OT, AUC30) for 15 µM of the HD1
aptamer.
FIGURE 7 | Images of thrombi formed inside capillaries of atheroma chips (AR) under flow conditions in HD1- (A) and HD22-treated (C) (both at 15 µM) blood
samples obtained from one volunteer in comparison to controls (B,D), respectively, at 12 min of measurements. Blue and red lines below the images correspond to
thrombi profile in the middle of capillaries, where high peaks correspond to high density of thrombi inside capillaries.
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TABLE 1 | Representative values of dissociation constants of HD1 and HD22
aptamer complexes with human thrombin measured in simulated body plasma
ionic buffer.
Incubation buffer KdHD1 ± SD (nM) KdHD22 ± SD (nM)
SBP 257.8 ± 15 97.6 ± 2.2
Kd, dissociation constants; SBP, simulated body plasma ionic buffer. Means and
standard deviation (SD) are presented.
In thrombin-induced platelet aggregation experiments, HD1
aptamer was a stronger anti-platelet agent than HD22 in PRP
as well as in WP (Figures 1A–D). Differences in the strength
of anti-platelet effects of HD1 and HD22 aptamers might be
explained considering the interaction of thrombin exosite I and
exosite II with platelet receptors. Exosite I interacts with the
PAR-1 receptor (Pica et al., 2017), representing a dominant
membrane component of thrombin-induced proteolytic platelet
activation mechanism (Nieman, 2016). HD1 aptamer blocks the
initiation of platelet aggregation preceded by proteolytic cleavage
of the PAR-1 receptor (Brien et al., 2001).
On the other hand, effects of the HD22 aptamer on
platelet aggregation reported here seem to be compatible
with a role of thrombin exosite II (Pica et al., 2017) in
activation of the GPIb-IX-V receptor, representing an additional
mechanism of thrombin-dependent platelet activation different
than proteolytical activation of PAR-1, the mechanism of which
is still not clear (De Candia et al., 2001; De Candia, 2012).
Weak anti-platelets effects of HD22 might be also link to
the blockage of exosite II which leads to slight inhibition of
hydrolysis of PAR-1 receptor following the action of exosite I
(De Candia et al., 2001; De Candia, 2012). Allosteric changes
and interdependences between exosite II, exosite I and the active
site of thrombin which could cause the reduction of strength of
interactions of PAR-1 with exosite I should also be considered
(Petrera et al., 2009).
Additionally, HD1 and HD22 showed non-specific
interactions under the absence of thrombin resulting in the
inhibition and enhancement of ristocetin-induced platelet
activation in PRP and WP, respectively (Figures 3A–D).
Aggregation of platelets evoked by ristocetin is dependent on
conformational changes of von Willebrand factor facilitating
the protein interaction with GPIb-IX-V receptor (Kang et al.,
2008; Obert et al., 2014) and that is why, ristocetin-induced
platelet aggregation (RIPA) test was used to a diagnosis of
von Willebrand disease (Horvath et al., 2004; Ruggeri, 2007;
Castaman et al., 2014).
Here was shown that HD1 and HD22 reduced
ristocetin-induced platelet aggregation in PRP (Figures 3C,D)
suggesting that HD1 and HD22 aptamers bind to GPIb-IX-
V receptor impeding interactions of soluble vWF with the
receptor resulting in the inhibition of the ristocetin-induced
response of platelets in the presence of plasma-derived vWF
known to interact with GPIb-IX-V receptor, in contrast to
platelet-derived vWF interacting rather with GPIIb-IIIa receptor
(Gralnick et al., 1991).
However, in WP, both HD1 and HD22 increased platelet
activation, most likely by direct interactions of HD1 and HD22
with GPIb-IX-V receptor leading to the release of vWF from
platelets α-granules which caused platelet aggregation mediated
by binding of secreted vWF to GPIIb-IIIa receptor in WPs
samples. The α-granules-derived vWF accounts only about 20%
of total protein in blood (Peyvandi et al., 2011; Mcgrath et al.,
2018; Verhenne et al., 2018) which means that the involvement
of α-granules-derived vWF in HD1 and HD22 effects in PRP or
in full blood might be negligible. However, it might well be that
this additional mechanism of HD1 and HD22 aptamers actions
could explain the presence of significance variabilities of obtained
results especially among platelets aggregation data and the need
of use of high doses of HD1 and HD22 in ex vivo T-TAS assay.
In contrast to a possible interactions of HD1 and HD22
aptamers with GPIb-IX-V receptor neither of the aptamers did
influenced collagen-induced platelet aggregation excluding the
interactions of HD1 and HD22 with GPVI receptor (Miura et al.,
2002; Nieswandt and Watson, 2003).
In the present work, we compared effects of thrombin
binding aptamers with that of dabigatran (50 ng/ml) that clearly
show that effects of most effective aptamer HD1 on thrombin-
induced platelet aggregation was weaker than dabigatran used
in the therapeutic range of concentration, underscoring weak
therapeutic potential of HD1 as reported in clinical trials (Mayer
et al., 2011; Vinholt et al., 2017; Zavyalova et al., 2017).
Independently of effects on platelets, HD22 (3 µM) but not
HD1 (3 µM), surprisingly displayed enhanced fluorogenic signal
production, assessed by calibrated automated thrombography
(CAT), an increasingly appreciated reference method for the
quantitative assessment of thrombin generation (Castoldi and
Rosing, 2011; Hemker and Kremers, 2013). Apart from the
weak anticoagulant effects of the HD22 aptamer, as evidenced
by a prolonged lag time and time to peak, HD22 increased
the height of the peak and ETP (Figure 4). We also observed
a higher fluorescence signal in measurements of fluorogenic
signal generation during CAT fluorogenic substrate cleavage by
thrombin in the presence of HD22 aptamer (3 µM) as compared
to control in buffer matrix while HD1 aptamer (3 µM) did not
show any effect. We hypothesized that these surprising results
of HD22 could be explained by the conformational changes of
exosite I and/or the active site of the thrombin caused by binding
of HD22 to exosite II, resulting in the limited coagulation factors
activation and enhancement of the catalytic activity of thrombin
toward the fluorogenic substrate (Fredenburgh et al., 1997; Bock
et al., 2007; Segers et al., 2007).
Similar effect was seen when, instead of CAT substrate,
fibrinogenesis was measured. We observed the acceleration of
fibrin formation by HD22 (3 µM) (Figure 5B) as evidenced
by shortened lag time and reduced t1/2 value as compared to
control, which supports the notion of HD22 interaction with
exosite II, induce changes in the conformation of thrombin. We
hypothesize that the active site of thrombin might be allosterically
changed toward acceleration of fibrinogen cleavage resulting in
accelerated fibrin generation and/or the affinity of thrombin
exosite I to fibrinogen may increase.
In contrast to the complex effects of HD22 on thrombin
and fibrin generation, HD1 inhibited thrombin generation in
a concentration-dependent manner (0.5–15 µM) and fibrin
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generation (3 µM), as evidenced by prolongation of lag time,
time to peak, and lowered endogenous thrombin potential (ETP)
in CAT measurements (Figure 4) and prolonged lag time and
t1/2 parameter (Figure 5A) as compared to controls in turbidity
measurements, which all support the major role of exosite I in
the activity of thrombin (Pospisil et al., 2003; Kretz et al., 2006;
Crawley et al., 2007).
Altogether, comparison of the effects of HD1 and HD22 on
thrombin generation and fibrin formation revealed strong and
clear-cut anti-coagulant effects of HD1 aptamer and modest
and more complex mechanisms of actions of HD22 aptamer
on coagulation and fibrin generation, underscoring the dynamic
nature of thrombin (Petrera et al., 2009; Malovichko et al., 2013;
Pica et al., 2017).
For the final readout of the thrombotic effects of HD1 and
HD22, we used the novel microchip-based chamber system
for thrombi formation in human whole blood (ex vivo) under
flow conditions (T-TAS). Using microchips covered by collagen
and tissue factor we compared effects of both aptamers.
This experimental approach demonstrated that HD1 (3 µM,
15 µM) displayed concentration-dependent anti-thrombotic
effects, as reflected by the delayed start of thrombus formation
(T10), prolonged occlusion time (OT) and reduced total
thrombogenicity (AUC30) (Figure 6) that was associated with
the reduction of the area covered by thrombi by approximately
30% in comparison with the control samples (Figure 7).
These results indicated that HD1 aptamer effectively limited
the interactions of fibrinogen and platelets receptors with
exosite I of thrombin as well as thrombin generation and
coagulation process.
In contrast to HD1, HD22 (3 µM, 15 µM) did not influence
significantly any measured parameters (Figures 6, 7). The
thrombogenic surface of AR chips, which were used during
experiments, induced robust thrombin production and platelet
activation. Even though blood samples are rich in soluble von
Willebrand factor which interacts fervently with platelet receptor
GPIb-IX-V and collagen under shear stress conditions (Gralnick
et al., 1991; Siedlecki et al., 1996; Andrews et al., 2003). Collagen
surfaces may also strongly activate platelets directly by the GPVI
receptor (Farndale, 2006).
Altogether, the weak anti-platelet effects of HD22 observed
in PRP or WP that we attributed to the GPIb-IX-V receptor,
and its weak anti-coagulation effects observed in CAT as well
as the effects of HD22 in non-catalytic fibrin polymerization
(Mosesson, 2007), are apparently of negligible importance
in thrombi formation in human blood inside AR chips,
whereby mechanisms of thrombin-mediated fibrin formation,
platelet activation and adhesion triggered by collagen, and TF
surface, are dominant.
To correlate pharmacological activity of HD1 and HD22
aptamers with their affinity to thrombin, we determined
Kd values for both using capillary electrophoresis (CE)
in simulated body plasma ionic buffer (SBP). Pica et al.
showed a sandwich complex of HD1 and HD22 with
thrombin (Pica et al., 2017). However, the influence of matrix
composition on conformation and complex stabilization have
not been fully elucidated. Measurements of aptamer affinity
to thrombin prepared in SBP showed stronger interaction
of HD22 than HD1 aptamer with thrombin. Kd values
obtained were equal to 97.6 nM and 257.8 nM for HD22
and HD1, respectively (Table 1). That difference can be
related to the longer oligonucleotide strain of HD22 aptamer
as compared to the length of the HD1 strain (Spiridonova
et al., 2015) but was not translated to better anti-thrombin
activity of HD22 as compared with HD1, due to a quite
different role of exosite I vs. exosite II in the regulation of
thrombin activity.
CONCLUSION
To conclude, HD1 but not HD22 can be considered as a
potent anti-thrombin agent. This result is compatible with
the major role of exosite I in platelet activation, thrombin
generation, fibrin generation and thrombus formation. The
exosite I interactions with PAR1, fibrinogen and coagulation
factors could all be involved (Verhamme et al., 2002; Bock
et al., 2007). HD22 aptamer interactions with thrombin
at exosite II displays weak anti-platelet and procoagulant
effects, without any evident anti-thrombotic effect, underscoring
the complex nature of exosite II-dependent regulation of
thrombin function, including direct interactions of the aptamer
with exosite II as well as allosteric interactions inside the
enzyme molecule. Finally, our results demonstrated non-
specific, thrombin-independent mechanisms of HD1 and HD22
action most likely linked to their interactions with GPIb-
IX-V receptor. Altogether, our results seem to question the
superiority of bivalent anti-thrombin aptamer binding to
exosite I and exosite II over those binding to exosite I
only, as has been recently proposed (Müller et al., 2008;
Hughes et al., 2017).
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